Medullary thyroid carcinoma (MTC) is a rare, often aggressive, neuroendocrine thyroid tumor with limited targeted treatment options, arising from calcitonin-producing C cells and sometimes associated with RET mutations. Researchers from the Mayo Clinic reported the potential of targeting DLL3 as a therapeutic strategy in MTC.
In a recent publication, researchers from The First Affiliated Hospital of Zhengzhou University (China) and collaborators investigated the association between phosphoglycerate kinase 1 (PGK1) expression in thyroid cancer tissues and clinicopathological features, postoperative recurrence and prognosis in papillary thyroid carcinoma (PTC). These observations may help advance clinical assessment and provide references for intervention strategies.
Anaplastic thyroid cancer (ATC) is a rare but aggressive form of thyroid cancer, accounting for nearly 50% of thyroid cancer-related deaths. Given its poor prognosis, the identification of new therapeutic strategies is a critical medical need. Molecular radiotherapy is an emerging field in oncology, and CD44v6, a cell surface antigen overexpressed in several cancers, has been proposed as a promising target for ATC treatment.
Differentiated thyroid cancers (DTC) and anaplastic thyroid cancers (ATC) often develop primary and acquired resistance to standard treatments. This highlights the need for new therapeutic strategies to treat these thyroid tumors. Previous research observed that the pyrimidine ring of the 2,4-diaminopyrimidine moiety could often form critical hydrogen bonds with kinases, leading to strong inhibitory activity.
Veracyte Inc. revealed plans to buy C2i Genomics Inc. at the J.P. Morgan Health Care Conference in San Francisco on Jan. 8, a move that will significantly expand its portfolio of cancer diagnostic and monitoring assays. The terms include $70 million in Veracyte shares to be paid at closing plus an addition $25 million payable in cash or Veracyte shares over the next two years if C2i achieves certain performance milestones.
Baird Medical Investment Holdings Ltd.’s disposable microwave ablation (MWA) needle was approved by China’s National Medical Products Administration for treatment of benign thyroid nodules, which will help the company build a portfolio of products for thyroid diseases.
Atreca Inc. and Xencor Inc. have mutually selected the first program from their strategic collaboration combining an Atreca-discovered antibody with Xencor's Xmab bispecific Fc domain and a cytotoxic T-cell binding domain (CD3).
Suzhou Zelgen Biopharmaceuticals Co. Ltd. reported a phase III trial testing the company’s deuterium-substituted sorafenib derivative donafenib in patients with progressive locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer met its primary endpoint following a preplanned interim analysis which found the drug significantly prolonged median progression-free survival vs. a placebo.
Suzhou Zelgen Biopharmaceuticals Co. Ltd. reported a phase III trial testing the company’s deuterium-substituted sorafenib derivative donafenib in patients with progressive locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer met its primary endpoint following a preplanned interim analysis which found the drug significantly prolonged median progression-free surviva vs. a placebo.
